News round-up for 5-9 May by DDW Senior Digital Content Editor Diana Spencer.

Our highlights this week demonstrate a variety of approaches to cancer treatment, including a BTK inhibitor, macrophage checkpoint inhibitor, and antibody-drug conjugates, at various stages of development.

The top stories:

First patient receives anti-CD24 macrophage checkpoint inhibitor

Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours.

Read more…

Calquence plus chemoimmunotherapy approved in the EU

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for previously untreated mantle cell lymphoma (MCL).

Read more…

Enedra secures financing for precision cancer therapies

Enedra Therapeutics has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers.

Read more…

ADCs show best-in-class potential for treating solid tumours

SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models.

Read more…

Partners advance virus-like particle platform for liver cancer

Hovione and Firstgene Life Sciences have announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by Firstgene.